The DAPA-HF (Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure) trial showed that treatment with a SGLT2 inhibitor was also effective for reducing the risk of HF-related events and decreasing NT-proBNP concentrations in patients with HFrEF, regardless of whether they had T2D [38]. Here, NPPB is linked to heart failure.